Page Title

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

Vakzine Projekt Management supports Memo Therapeutics AG in the clinical development of MTX-COVAB, human-derived antibody against SARS-CoV-2 which has shown excellent neutralizing efficacy against both the original virus as well as the UK variant. Read more!